Also trades as: FBIOP (NASDAQ) · $vol 0M
FBIO NASDAQ
Fortress Biotech, Inc.
1W: -11.0%
1M: -25.6%
3M: -31.2%
YTD: -49.6%
1Y: -20.7%
3Y: -56.3%
5Y: -96.2%
$2.03
-0.04 (-1.93%)
Weekly Expected Move ±4.5%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships0
As Filer
counterparties named
4
As Counterparty
mentioned by others
2022-05-16
Earliest Filing
2025-03-10
Latest Filing
Mentioned As Counterparty
4 mentionsOther companies that named FBIO in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| FBIOP Fortress Biotech, Inc. | partner | Majority-controlled parent of the target and signatory to support, royalty, and transition service agreements. | 2025-03-10 | View |
| ATXI AVENUE THERAPEUTICS, INC. | investor | Acquired 767,085 shares of common stock in a private placement transaction. | 2023-09-08 | View |
| ATXI AVENUE THERAPEUTICS, INC. | target | Transferred majority ownership of Baergic to Avenue Therapeutics in exchange for assumption of liabilities. | 2022-11-08 | View |
| ATXI AVENUE THERAPEUTICS, INC. | partner | Parent company transferring ownership of subsidiary Baergic Bio, Inc. to Avenue Therapeutics, Inc. | 2022-05-16 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR